Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05565313 · ClinicalTrials.gov registry record

Predicting Radiological Extranodal Extension in Oropharyngeal Carcinoma Patients Using AI

A clinical trial of Head and Neck Carcinoma, sponsored by Maastricht Radiation Oncology.

Active
Registry status
900
Enrollment target
3
Study locations

NCT05565313 is a study of Head and Neck Carcinoma that is active but no longer recruiting, run by Maastricht Radiation Oncology. The registered enrollment target is 900 participants, above the 383-participant average among 30 other Head and Neck Carcinoma trials with a reported enrollment target (135% higher). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05565313, a study of Head and Neck Carcinoma, is active but no longer recruiting, sponsored by Maastricht Radiation Oncology.

ACTIVE NOT RECRUITING
Registry status
900 participants
Enrollment target
3
Study locations

Study Summary

Development and validation of a model that predicts rENE from radiological imaging using annotated / labeled scans by means of deep learning

Conditions Studied

Study Locations (3)

Massachusetts

  • Harvard Medical School and clinical faculty at Dana-Farber Cancer Institute/Brigham and Women's Hospital - Boston

Ontario

  • Princess Margaret Cancer Centre - Toronto

Limburg

  • Maastro - Maastricht

Trial Details

FieldValue
Enrollment Target 900 participants
Start Date 2022-03-22
Est. Completion 2026-08-01

Sponsor

Maastricht Radiation Oncology

2 total trials

What the Registry Record Tells You About NCT05565313

The ClinicalTrials.gov registry entry for NCT05565313 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 900 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 383-participant average among 30 other Head and Neck Carcinoma trials with a reported enrollment target (135% higher). The listed sponsor is Maastricht Radiation Oncology, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Head and Neck Carcinoma appearing as the primary indexed condition, and to 0 interventions.

NCT05565313 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Massachusetts, Ontario, Limburg.

Frequently Asked Questions

What is clinical trial NCT05565313 about?

NCT05565313 is a clinical study titled "Predicting Radiological Extranodal Extension in Oropharyngeal Carcinoma Patients Using AI". Development and validation of a model that predicts rENE from radiological imaging using annotated / labeled scans by means of deep learning

What is the current status of trial NCT05565313?

This trial is currently active not recruiting. The enrollment target is 900 participants. The study started on 2022-03-22. Estimated completion is 2026-08-01.

What conditions does trial NCT05565313 study?

This clinical trial studies the following conditions: Head and Neck Carcinoma.

Who is sponsoring clinical trial NCT05565313?

This trial is sponsored by Maastricht Radiation Oncology, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05565313 being conducted?

This trial has 3 study locations across Massachusetts, Ontario, Limburg. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Head and Neck Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.